Kidney & Urinary Tract

This study is for the treatment of localized, muscle-invasive bladder cancer.

Primary disease category: 
Secondary disease category(ies): 

The purpose of this study is to determine the maximum tolerated dose of RX-0201, up to a target dose of 250 mg/m^2/day, when given in combination with everolimus (Stage 1), and to assess the safety and efficacy of RX-0201 plus everolimus, in subjects with metastatic renal cell cancer (Stage 2).

Primary disease category: 
Secondary disease category(ies): 

This study is for the treatment of advanced transitional cell carcinoma.

Primary disease category: 
Secondary disease category(ies): 
Subscribe to RSS - Kidney & Urinary Tract